Video: Frontage Laboratories, Inc 2019
Frontage is a CRO providing integrated, scientifically-driven research, analytical and product development services throughout the drug discovery and development process to enable biopharmaceutical companies to achieve their drug development goals.
We offer our clients comprehensive services in analytical testing and formulation development, drug metabolism and pharmacokinetics (DMPK), bioanalysis, preclinical safety and toxicology and early phase clinical studies. We have enabled many innovator, generic and consumer health companies of all sizes to file IND, NDA, ANDA, BLA and 505(b)(2) submissions in global markets allowing for successful development of important therapies and products for patients.
We successfully assist clients to advance hundreds of molecules through development to commercial launch in global markets. We are committed to providing rigorous scientific expertise to ensure the highest quality and compliance.
Webinar: Bioanalysis of Liposome Drugs by LC-MS/MS
This webinar presents history, introduction, applications and regulatory considerations for liposomal drugs and also discusses the development and validation of LC-MS/MS methods for the quantitation of total (encapsulated plus free), encapsulated and free drug concentrations for liposome drug products.
Kai Wang, Ph.D
Associate Director, Bioanalytical Services
Fact Sheet: Tobacco
With over 20 years of experience in execution of comprehensive Phase I-IIa studies, Frontage Clinical Services has full capabilities to conduct a broad range of study types (e.g. PK, confinement and ambulatory) in support of tobacco related studies. With extensive expertise in a wide variety of delivery systems, we are well-positioned to conduct tobacco-focused clinical research studies.
Fact Sheet: DMPK
DMPK studies can provide critical data during discovery and development of pharmaceutical and agrochemical products. Frontage’s DMPK services, performed in accredited facilities, can help support lead drug candidate or chemical selection, or help you meet specific regulatory requirements.
Poster: Characterization of ADC by LC/MS/MS
Antibody drug conjugates (ADCs) has become promising therapy for the treatment of cancers. Among all the ADCs
under developing, 2/3 of them are interchain cysteine linked ADCs. The ADCs are manufactured by partially reduce
the 4 pairs of interchain disulfide bond followed by conjugate cytotoxic payloads to the thiols, as a consequence, the
antibodies are linked with 0, 2, 4, 6, 8 drugs. The drug to antibody ratio (DAR) and the drug linking position are
important parameters that affect the therapeutic effects and need to be well characterized.
Infographic: ADC 2019
ADCs (Antibody Drug Conjugates) combine the best of two modalities, toxic efficacy and antibody specificity. The result is an improved therapeutic window with fewer side effects. However, the bioanalytical requirements for PK analysis also require a multifaceted approach. Here-in we describe various mass spectrometry based strategies Frontage has successfully applied in the bioanalysis of ADC’s for clinical and preclinical studies.